Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136741 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Nektar Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
- 20
- Study locations
NCT06136741: Active Phase 2 study of Moderate-to-Severe Atopic Dermatitis, sponsored by Nektar Therapeutics.
NCT06136741 is a Phase 2 study of Moderate-to-Severe Atopic Dermatitis that is active but no longer recruiting, run by Nektar Therapeutics. The registered enrollment target is 396 participants, below the 569-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136741, a Phase 2 study of Moderate-to-Severe Atopic Dermatitis, is active but no longer recruiting, sponsored by Nektar Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.
Primary Outcome
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rezpegaldesleukin
Study Locations (20)
Florida
- Nektar Investigative Site - Hialeah
- Nektar Investigative Site - Hollywood
- Nektar Investigative Site - Miami
- Nektar Investigative Site - Miami Lakes
- Nektar Investigative Site - St. Petersburg
- Nektar Investigative Site - Tampa
California
- Nektar Investigative Site - Fountain Valley
- Nektar Investigative Site - Los Angeles
- Nektar Investigative Site - Los Angeles
- Nektar Investigative Site - Los Angeles
- Nektar Investigative Site - Santa Monica
Indiana
- Nektar Investigative Site - Clarksville
- Nektar Investigative Site - Indianapolis
Michigan
- Nektar Investigative Site - Flint
- Nektar Investigative Site - Troy
Arkansas
- Nektar Investigative Site - Bryant
Georgia
- Nektar Investigative Site - Marietta
Kentucky
- Nektar Investigative Site - Louisville
Nevada
- Nektar Investigative Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT06136741 still lists
NCT06136741 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 569-participant average among 4 other Moderate-to-Severe Atopic Dermatitis trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Moderate-to-Severe Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06136741 names 20 study sites across 9 states, led by Florida, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT06136741 about?
NCT06136741 is a clinical study titled "A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis". This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for scre...
What is the current status of trial NCT06136741?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2023-11-15. Estimated completion is 2026-12-31.
What conditions does trial NCT06136741 study?
This clinical trial studies the following conditions: Moderate-to-Severe Atopic Dermatitis.
What interventions are being tested in trial NCT06136741?
The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT06136741?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136741 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-Severe Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
COMPLETED · Phase 2
-
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
COMPLETED · Phase 3
-
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI